Relationship between Treatment Effects on Progression-Free Survival and Overall Survival in Multiple Myeloma: A Systematic Review and Meta-Analysis of Published Clinical Trial Data
Authors:
- Bin ZhangBZBin Zhang
- Virginia M. RosenVRVirginia M. Rosen
- Victoria ZarotskyVZVictoria Zarotsky
- J. Blake BartlettJBJ. Blake Bartlett
- Pralay MukhopadhyayPMPralay Mukhopadhyay
- Samuel WagnerSWSamuel Wagner
- Catherine DavisCDCatherine Davis
- 20 February 2015
- journal article
- research article
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 38 (3) , 88-94
Abstract
Background: Demonstrating improved overall survival (OS) with new multiple myeloma (MM) treatments is becoming difficult because of extended survival, so progression-free survival (PFS) is commonly used as a surrogate endpoint for OS. We evaluated PFS as a potential surrogate for OS by examining whether observed treatment effects on PFS are positively associated with treatment effects on OS in MM. Methods: A systematic literature review identified 21 randomized control trials reporting hazard ratios (HRs) for treatment effects on PFS and OS. Pearson's r estimated the relationship between HRs (HRPFS and HROS), and between log-transformed HRs (log(HRPFS) and log(HROS)). R2 values were estimated from linear regression models of the HR and the log(HR) relationships. Sensitivity and subgroup analyses examined the robustness of the HR findings. Results: Positive correlations were found between HRPFS and HROS (r = 0.82; p < 0.0001) and between log(HRPFS) and log(HROS) (r = 0.80; p < 0.0001). Linear regression models produced R2 values of 0.67 and 0.63 when regressing HROS on HRPFS, and log(HROS) on log(HRPFS), respectively. Sensitivity analyses supported the HR findings. Conclusion: This analysis provides evidence for a positive association between treatment effects on PFS and OS. Studies involving patient level data are necessary to confirm whether PFS is a valid surrogate for OS in MM.Keywords
This publication has 42 references indexed in Scilit:
- Time-dependent endpoints as predictors of overall survival in multiple myelomaBMC Cancer, 2013
- Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationBlood, 2011
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialThe Lancet, 2010
- Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myelomaHaematologica, 2010
- Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literatureAnnals of Oncology, 2009
- Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trialsInternational Journal of Clinical Oncology, 2009
- Multiple MyelomaCurrent Problems in Cancer, 2009
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaNew England Journal of Medicine, 2007
- Continuous prednisoloneversusconventional prednisolone with VMCP–interferon‐α2b as first‐line chemotherapy in elderly patients with multiple myelomaBritish Journal of Haematology, 2005
- Correlations redux.Psychological Bulletin, 1995